Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Nuvaxovid Market Size And Revenue Forecast Through 2030
The historical expansion was driven by worldwide efforts to combat the COVID-19 pandemic, emergency use approvals granted for vaccines, the broadening of extensive vaccination campaigns, a rise in government health spending, and the swift buildup of vaccine production capabilities.
The predicted expansion in the upcoming period is driven by sustained need for booster doses, heightened emphasis on vaccines tailored to emerging variants, broader worldwide immunization efforts, a growing inclination toward varied vaccine technologies, and reinforced measures for pandemic readiness. Key developments expected during this time comprise the rising use of protein-based vaccine platforms, intensified attention to adjuvants that improve immune responses, wider deployment of vaccines with optimized cold-chain logistics, increased preference for COVID-19 shots that do not rely on mRNA, and more robust tracking of vaccine safety and effectiveness.
Download A Free Sample Report For Comprehensive Market Insights:
Nuvaxovid Market Growth Drivers And Industry Catalysts
The anticipated expansion of the nuvaxovid market is being propelled by the growing frequency of infectious diseases. These illnesses stem from dangerous microorganisms such as bacteria, viruses, fungi, or parasites and spread via human interaction or environmental exposure. The uptick in such diseases is driven by factors like worldwide travel, urban expansion, climatic shifts, resistance to antimicrobials, and the appearance of novel pathogens, all of which heighten their overall prevalence. By offering an effective COVID-19 vaccine that curbs transmission and helps reduce the virus’s global reach, nuvaxovid plays a role in countering this trend. As an example, in March 2023, the Office for National Statistics, a UK government body, reported that COVID-19 infections in England were on the rise, with around 2.66% of the population (1 in 40 people) testing positive during the week ending 13 March 2023; meanwhile, uncertain trends were noted in Wales at 2.41% (1 in 40), Scotland at 2.59% (1 in 40), and Northern Ireland at 1.42% (1 in 70). The infection rate climbed in the North West, East Midlands, and South East, impacting age groups from 2 years up to school Year 11 as well as individuals aged 50 and over, and hospital admissions for confirmed COVID-19 in England reached 10.62 per 100,000 people by the week ending 19 March 2023, while 619 COVID-19-related deaths occurred in the UK by the week ending 17 March 2023, an increase from 605 the prior week. Consequently, the rising incidence of infectious diseases is fueling the nuvaxovid market.
Growing demand for vaccines is set to drive the expansion of the nuvaxovid market moving forward. Vaccines are biological agents that activate the immune system, allowing the body to identify and combat specific infectious diseases. This demand is climbing due to higher rates of infectious illnesses, enhanced public understanding of health safeguards, progress in vaccine research, and an increased emphasis on preventive healthcare. By delivering an updated formulation that targets new COVID-19 variants, nuvaxovid meets this rising need, ensuring wider coverage and bolstering worldwide immunization programs. For example, in November 2024, the Centers for Disease Control and Prevention (CDC), a U.S. federal agency, indicated that by October 2024, 13.7% of U.S. adults aged 18 and older had obtained the 2024–25 COVID-19 vaccine, whereas 24.5% had received the flu vaccine for the same period. The highest vaccination uptake was among those aged 65 and older, with 29.1% getting the COVID-19 vaccine and 43.1% the flu shot. Hence, the heightened demand for vaccines is stimulating the nuvaxovid market.
Nuvaxovid Market Segment Landscape And Growth Potential
The nuvaxovid market covered in this report is segmented –
1) By Clinical Indication: Primary Immunization, Booster Immunization, Immunocompromised Patients, Elderly Population, Pediatric Immunization, Travel Immunization
2) By End Use: Hospitals, Clinics, Ambulatory Care, Home Care
3) By Distribution Channel: Retail Pharmacies, Online Sales, Government Programs
Nuvaxovid Market Trends Influencing Long-Term Demand
A major driver in the Nuvaxovid market involves the creation of advanced vaccine delivery mechanisms, including updated COVID-19 vaccines, which offer effective prevention against COVID-19 while tackling new variants and boosting global immunization initiatives. An updated COVID-19 vaccine represents a refined version of its predecessor, specifically engineered to enhance immunity against fresh circulating SARS-CoV-2 strains, thereby maintaining robust protection against severe illness and hospital admissions. As an example, in October 2024, Novavax, Inc., a US biotechnology firm, announced that the European Commission had granted marketing authorization for its updated 2024-2025 Nuvaxovid COVID-19 vaccine (recombinant, adjuvanted), intended for individuals aged 12 and older to prevent COVID-19 across the European Union. This upgraded vaccine targets the JN.1 lineage and demonstrates cross-reactivity with numerous other variants. This authorization is notable because it widens availability of an improved vaccine formulation designed to counter evolving COVID-19 variants, thereby reinforcing continuous global vaccination campaigns.
Nuvaxovid Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the nuvaxovid market are Novavax Inc.
Access The Complete Nuvaxovid Market Report:
Nuvaxovid Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the nuvaxovid market in 2025. The regions covered in the nuvaxovid market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model